Kazia Therapeutics Ltd
ASX:KZA
Kazia Therapeutics Ltd
ASX:KZA
Price:
0.08 AUD
Market Closed
Updated:
May 3, 2024
Kazia Therapeutics Ltd
Operating Income
|
Kazia Therapeutics Ltd
Operating Income Peer Comparison
Comparables:
IMM
MSB
CSL
CUV
TLX
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Kazia Therapeutics Ltd
ASX:KZA
|
Operating Income
-AU$24.1m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-28%
|
|
|
Immutep Ltd
ASX:IMM
|
Operating Income
-AU$46.9m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-13%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Operating Income
-$55.3m
|
CAGR 3-Years
21%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Operating Income
$3.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Operating Income
AU$50.8m
|
CAGR 3-Years
36%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Operating Income
AU$17.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Kazia Therapeutics Ltd's Operating Income?
Operating Income
-24.1m
AUD
-24.1m
AUD
Based on the financial report for Jun 30, 2023, Kazia Therapeutics Ltd's Operating Income amounts to -24.1m AUD.
What is Kazia Therapeutics Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-28%
-28%
Over the last year, the Operating Income growth was 5%. The average annual Operating Income growth rates for Kazia Therapeutics Ltd have been -26% over the past three years , -14% over the past five years , and -28% over the past ten years .
You don't have any saved screeners yet
